SEC Company Response from Opus Genetics, Inc. (IRD) (CIK 0001228627) (IRD) — Jul 7, 2017
Opus Genetics, Inc. (IRD) (CIK 0001228627)
Date: July 7, 2017 · CIK: 0001228627 · Accession: 0001140361-17-027469
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218285
Letter
Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road, Suite 455
Rockville, Maryland 20850
July 7, 2017
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
Rexahn Pharmaceuticals, Inc.
Registration Statement on Form S-3 (File No. 333-218285)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Rexahn Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare the Registration Statement effective as of 5:00 p.m., Eastern Daylight Time, on July 11, 2017, or as soon thereafter as possible.
Please feel free to direct any questions or comments concerning this request to William Intner of Hogan Lovells US LLP at (410) 659-2778.
Very truly yours,
Rexahn Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm Rexahn Pharmaceuticals, Inc. 15245 Shady Grove Road, Suite 455 Rockville, Maryland 20850 July 7, 2017 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Rexahn Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-218285) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Rexahn Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare the Registration Statement effective as of 5:00 p.m., Eastern Daylight Time, on July 11, 2017, or as soon thereafter as possible. Please feel free to direct any questions or comments concerning this request to William Intner of Hogan Lovells US LLP at (410) 659-2778. Very truly yours, Rexahn Pharmaceuticals, Inc. /s/ Tae Heum Jeong By: Tae Heum Jeong Title: Senior Vice President and Chief Financial Officer